Application | Comment | Organism |
---|---|---|
drug development | bacterial signal peptidase I (SPase) is a target for development of beta-lactam anti-bacterial inhibitors | Staphylococcus epidermidis |
drug development | bacterial signal peptidase I (SPase) is a target for development of beta-lactam anti-bacterial inhibitors | Yersinia pestis |
drug development | bacterial signal peptidase I (SPase) is a target for development of beta-lactam anti-bacterial inhibitors | Escherichia coli |
Inhibitors | Comment | Organism | Structure |
---|---|---|---|
(5S,6S)-3-[(2-aminoethyl)sulfanyl]-6-[(1R)-1-hydroxyethyl]-7-oxo-4-thia-1-azabicyclo[3.2.0]hept-2-ene-2-carboxylic acid | IC50 is 0.00063 mg/l | Escherichia coli | |
(5S,6S)-3-[(2-aminoethyl)sulfanyl]-6-[(1R)-1-hydroxyethyl]-7-oxo-4-thia-1-azabicyclo[3.2.0]hept-2-ene-2-carboxylic acid | - |
Staphylococcus epidermidis | |
(5S,6S)-3-[(2-aminoethyl)sulfanyl]-6-[(1R)-1-hydroxyethyl]-7-oxo-4-thia-1-azabicyclo[3.2.0]hept-2-ene-2-carboxylic acid | - |
Yersinia pestis | |
(5S,6S)-3-[[2-(carbamoyloxy)ethyl]sulfanyl]-6-[(1R)-1-hydroxyethyl]-7-oxo-4-thia-1-azabicyclo[3.2.0]hept-2-ene-2-carboxylic acid | IC50 is 0.00096 mg/l | Escherichia coli | |
(5S,6S)-3-[[2-(carbamoyloxy)ethyl]sulfanyl]-6-[(1R)-1-hydroxyethyl]-7-oxo-4-thia-1-azabicyclo[3.2.0]hept-2-ene-2-carboxylic acid | - |
Staphylococcus epidermidis | |
(5S,6S)-3-[[2-(carbamoyloxy)ethyl]sulfanyl]-6-[(1R)-1-hydroxyethyl]-7-oxo-4-thia-1-azabicyclo[3.2.0]hept-2-ene-2-carboxylic acid | - |
Yersinia pestis | |
(5S,6S)-3-[[2-(dimethylamino)ethyl]sulfanyl]-6-[(1R)-1-hydroxyethyl]-7-oxo-4-thia-1-azabicyclo[3.2.0]hept-2-ene-2-carboxylic acid | IC50 is 0.00395 mg/l | Escherichia coli | |
(5S,6S)-3-[[2-(dimethylamino)ethyl]sulfanyl]-6-[(1R)-1-hydroxyethyl]-7-oxo-4-thia-1-azabicyclo[3.2.0]hept-2-ene-2-carboxylic acid | - |
Staphylococcus epidermidis | |
(5S,6S)-3-[[2-(dimethylamino)ethyl]sulfanyl]-6-[(1R)-1-hydroxyethyl]-7-oxo-4-thia-1-azabicyclo[3.2.0]hept-2-ene-2-carboxylic acid | - |
Yersinia pestis | |
(5S,6S)-3-[[3-(dimethylcarbamoyl)cyclopentyl]sulfanyl]-6-[(1R)-1-hydroxyethyl]-7-oxo-4-thia-1-azabicyclo[3.2.0]hept-2-ene-2-carboxylic acid | IC50 is 0.00122 mg/l | Escherichia coli | |
(5S,6S)-3-[[3-(dimethylcarbamoyl)cyclopentyl]sulfanyl]-6-[(1R)-1-hydroxyethyl]-7-oxo-4-thia-1-azabicyclo[3.2.0]hept-2-ene-2-carboxylic acid | - |
Staphylococcus epidermidis | |
(5S,6S)-3-[[3-(dimethylcarbamoyl)cyclopentyl]sulfanyl]-6-[(1R)-1-hydroxyethyl]-7-oxo-4-thia-1-azabicyclo[3.2.0]hept-2-ene-2-carboxylic acid | - |
Yersinia pestis | |
(5S,6S)-6-[(1R)-1-hydroxyethyl]-3-([2-[(iminomethyl)amino]ethyl]sulfanyl)-7-oxo-4-thia-1-azabicyclo[3.2.0]hept-2-ene-2-carboxylic acid | IC50 is 0.00104 mg/l | Escherichia coli | |
(5S,6S)-6-[(1R)-1-hydroxyethyl]-3-([2-[(iminomethyl)amino]ethyl]sulfanyl)-7-oxo-4-thia-1-azabicyclo[3.2.0]hept-2-ene-2-carboxylic acid | - |
Staphylococcus epidermidis | |
(5S,6S)-6-[(1R)-1-hydroxyethyl]-3-([2-[(iminomethyl)amino]ethyl]sulfanyl)-7-oxo-4-thia-1-azabicyclo[3.2.0]hept-2-ene-2-carboxylic acid | - |
Yersinia pestis | |
(5S,6S)-6-[(1R)-1-hydroxyethyl]-3-[(2-hydroxyethyl)sulfanyl]-7-oxo-4-thia-1-azabicyclo[3.2.0]hept-2-ene-2-carboxylic acid | IC50 is 0.00149 mg/l | Escherichia coli | |
(5S,6S)-6-[(1R)-1-hydroxyethyl]-3-[(2-hydroxyethyl)sulfanyl]-7-oxo-4-thia-1-azabicyclo[3.2.0]hept-2-ene-2-carboxylic acid | - |
Staphylococcus epidermidis | |
(5S,6S)-6-[(1R)-1-hydroxyethyl]-3-[(2-hydroxyethyl)sulfanyl]-7-oxo-4-thia-1-azabicyclo[3.2.0]hept-2-ene-2-carboxylic acid | - |
Yersinia pestis | |
(5S,6S)-6-[(1R)-1-hydroxyethyl]-3-[[2-(methylamino)ethyl]sulfanyl]-7-oxo-4-thia-1-azabicyclo[3.2.0]hept-2-ene-2-carboxylic acid | IC50 is 0.00637 mg/l | Escherichia coli | |
(5S,6S)-6-[(1R)-1-hydroxyethyl]-3-[[2-(methylamino)ethyl]sulfanyl]-7-oxo-4-thia-1-azabicyclo[3.2.0]hept-2-ene-2-carboxylic acid | - |
Staphylococcus epidermidis | |
(5S,6S)-6-[(1R)-1-hydroxyethyl]-3-[[2-(methylamino)ethyl]sulfanyl]-7-oxo-4-thia-1-azabicyclo[3.2.0]hept-2-ene-2-carboxylic acid | - |
Yersinia pestis | |
(5S,6S)-6-[(1R)-1-hydroxyethyl]-7-oxo-3-[[(1R)-3-oxocyclopentyl]sulfanyl]-4-thia-1-azabicyclo[3.2.0]hept-2-ene-2-carboxylic acid | IC50 is 0.00116 mg/l | Escherichia coli | |
(5S,6S)-6-[(1R)-1-hydroxyethyl]-7-oxo-3-[[(1R)-3-oxocyclopentyl]sulfanyl]-4-thia-1-azabicyclo[3.2.0]hept-2-ene-2-carboxylic acid | - |
Staphylococcus epidermidis | |
(5S,6S)-6-[(1R)-1-hydroxyethyl]-7-oxo-3-[[(1R)-3-oxocyclopentyl]sulfanyl]-4-thia-1-azabicyclo[3.2.0]hept-2-ene-2-carboxylic acid | - |
Yersinia pestis | |
(5S,6S)-6-[(1R)-1-hydroxyethyl]-7-oxo-3-[[(3R)-pyrrolidin-3-yl]sulfanyl]-4-thia-1-azabicyclo[3.2.0]hept-2-ene-2-carboxylic acid | IC50 is 0.00175 mg/l | Escherichia coli | |
(5S,6S)-6-[(1R)-1-hydroxyethyl]-7-oxo-3-[[(3R)-pyrrolidin-3-yl]sulfanyl]-4-thia-1-azabicyclo[3.2.0]hept-2-ene-2-carboxylic acid | - |
Staphylococcus epidermidis | |
(5S,6S)-6-[(1R)-1-hydroxyethyl]-7-oxo-3-[[(3R)-pyrrolidin-3-yl]sulfanyl]-4-thia-1-azabicyclo[3.2.0]hept-2-ene-2-carboxylic acid | - |
Yersinia pestis | |
(5S,6S)-6-[(1R)-1-hydroxyethyl]-7-oxo-3-[[(3S)-pyrrolidin-3-yl]sulfanyl]-4-thia-1-azabicyclo[3.2.0]hept-2-ene-2-carboxylic acid | IC50 is 0.00080 mg/l | Escherichia coli | |
(5S,6S)-6-[(1R)-1-hydroxyethyl]-7-oxo-3-[[(3S)-pyrrolidin-3-yl]sulfanyl]-4-thia-1-azabicyclo[3.2.0]hept-2-ene-2-carboxylic acid | - |
Staphylococcus epidermidis | |
(5S,6S)-6-[(1R)-1-hydroxyethyl]-7-oxo-3-[[(3S)-pyrrolidin-3-yl]sulfanyl]-4-thia-1-azabicyclo[3.2.0]hept-2-ene-2-carboxylic acid | - |
Yersinia pestis | |
(5S,6S)-6-[(1R)-1-hydroxyethyl]-7-oxo-3-[[2-(pyridin-2-yl)ethyl]sulfanyl]-4-thia-1-azabicyclo[3.2.0]hept-2-ene-2-carboxylic acid | IC50 is 0.00131 mg/l | Escherichia coli | |
(5S,6S)-6-[(1R)-1-hydroxyethyl]-7-oxo-3-[[2-(pyridin-2-yl)ethyl]sulfanyl]-4-thia-1-azabicyclo[3.2.0]hept-2-ene-2-carboxylic acid | - |
Staphylococcus epidermidis | |
(5S,6S)-6-[(1R)-1-hydroxyethyl]-7-oxo-3-[[2-(pyridin-2-yl)ethyl]sulfanyl]-4-thia-1-azabicyclo[3.2.0]hept-2-ene-2-carboxylic acid | - |
Yersinia pestis | |
(5S,6S)-6-[(2R)-2-hydroxypropyl]-7-oxo-4-thia-1-azabicyclo[3.2.0]hept-2-ene-2-carboxylic acid | IC50 is 0.00299 mg/l | Escherichia coli | |
(5S,6S)-6-[(2R)-2-hydroxypropyl]-7-oxo-4-thia-1-azabicyclo[3.2.0]hept-2-ene-2-carboxylic acid | - |
Staphylococcus epidermidis | |
(5S,6S)-6-[(2R)-2-hydroxypropyl]-7-oxo-4-thia-1-azabicyclo[3.2.0]hept-2-ene-2-carboxylic acid | - |
Yersinia pestis | |
additional information | beta-lactam antibiotics, one of the most important class of human therapeutics, act via the inhibition of penicillin-binding proteins (PBPs). Bacterial type I signal peptidase is evolutionarily related to the PBPs, but the stereochemistry of its substrates and its catalytic mechanism suggest that beta-lactams with the 5S stereochemistry, as opposed to the 5R stereochemistry of the traditional beta-lactams, are required for inhibition. Synthesis and evaluation of a variety of 5S penem derivatives and identify several with promising activity against both a Gram-positive and a Gram-negative bacterial pathogen, overview. The 5S beta-lactams possess significant antibacterial activity | Escherichia coli | |
additional information | beta-lactam antibiotics, one of the most important class of human therapeutics, act via the inhibition of penicillin-binding proteins (PBPs). Bacterial type I signal peptidase is evolutionarily related to the PBPs, but the stereochemistry of its substrates and its catalytic mechanism suggest that beta-lactams with the 5S stereochemistry, as opposed to the 5R stereochemistry of the traditional beta-lactams, are required for inhibition. Synthesis and evaluation of a variety of 5S penem derivatives and identify several with promising activity against both a Gram-positive and a Gram-negative bacterial pathogen, overview. The 5S beta-lactams possess significant antibacterial activity, MIC values against Staphylococcus epidermidis, overview | Staphylococcus epidermidis | |
additional information | beta-lactam antibiotics, one of the most important class of human therapeutics, act via the inhibition of penicillin-binding proteins (PBPs). Bacterial type I signal peptidase is evolutionarily related to the PBPs, but the stereochemistry of its substrates and its catalytic mechanism suggest that beta-lactams with the 5S stereochemistry, as opposed to the 5R stereochemistry of the traditional beta-lactams, are required for inhibition. Synthesis and evaluation of a variety of 5S penem derivatives and identify several with promising activity against both a Gram-positive and a Gram-negative bacterial pathogen, overview. The 5S beta-lactams possess significant antibacterial activity, MIC values against Yersinia pestis, overview | Yersinia pestis | |
prop-2-en-1-yl (5S,6S)-6-[(2R)-2-hydroxypropyl]-7-oxo-4-thia-1-azabicyclo[3.2.0]hept-2-ene-2-carboxylate | crystal structure of enzyme-bound 1, PDB ID 1B12 | Escherichia coli | |
prop-2-en-1-yl (5S,6S)-6-[(2R)-2-hydroxypropyl]-7-oxo-4-thia-1-azabicyclo[3.2.0]hept-2-ene-2-carboxylate | - |
Staphylococcus epidermidis | |
prop-2-en-1-yl (5S,6S)-6-[(2R)-2-hydroxypropyl]-7-oxo-4-thia-1-azabicyclo[3.2.0]hept-2-ene-2-carboxylate | - |
Yersinia pestis |
Organism | UniProt | Comment | Textmining |
---|---|---|---|
Escherichia coli | P00803 | - |
- |
Escherichia coli MG1655 | P00803 | - |
- |
Staphylococcus epidermidis | - |
- |
- |
Staphylococcus epidermidis RP26A | - |
- |
- |
Yersinia pestis | - |
- |
- |
Yersinia pestis KIM+6 | - |
- |
- |
Substrates | Comment Substrates | Organism | Products | Comment (Products) | Rev. | Reac. |
---|---|---|---|---|---|---|
(4-(4-dimethylaminophenylazo)benzoyl)-AGHDAHASET-(5-((2-aminoethyl)amino)-naphthalene-1-sulfonic acid) + H2O | - |
Escherichia coli | (4-(4-dimethylaminophenylazo)benzoyl)-AGHDAHA + SET-(5-((2-aminoethyl)amino)-naphthalene-1-sulfonic acid) | - |
? | |
(4-(4-dimethylaminophenylazo)benzoyl)-AGHDAHASET-(5-((2-aminoethyl)amino)-naphthalene-1-sulfonic acid) + H2O | - |
Escherichia coli MG1655 | (4-(4-dimethylaminophenylazo)benzoyl)-AGHDAHA + SET-(5-((2-aminoethyl)amino)-naphthalene-1-sulfonic acid) | - |
? |
Synonyms | Comment | Organism |
---|---|---|
SPase | - |
Staphylococcus epidermidis |
SPase | - |
Yersinia pestis |
SPase | - |
Escherichia coli |
type I signal peptidase | - |
Staphylococcus epidermidis |
type I signal peptidase | - |
Yersinia pestis |
type I signal peptidase | - |
Escherichia coli |
IC50 Value | IC50 Value Maximum | Comment | Organism | Inhibitor | Structure |
---|---|---|---|---|---|
additional information | - |
IC50 values of 0.63-3.95 microgram per ml | Escherichia coli | additional information |
General Information | Comment | Organism |
---|---|---|
evolution | bacterial type I signal peptidase is evolutionarily related to the penicillin-binding proteins (PBPs) | Staphylococcus epidermidis |
evolution | bacterial type I signal peptidase is evolutionarily related to the penicillin-binding proteins (PBPs) | Yersinia pestis |
evolution | bacterial type I signal peptidase is evolutionarily related to the penicillin-binding proteins (PBPs) | Escherichia coli |